Du verkar använda en bredare skärm. Vill du aktivera en bredare visningsupplevelse på denna sida?
Faron ESMO 2025

Av Inderes
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.